ERBB2 and breast cancer: In line with this, recent evidence obtained analyzing 2 cohorts of Trastuzumab treated patients and a fully humanized immunocompetent ex vivo model of HER2-positive BC identified a population of TGF-β-activated CAFs specific of tumors resistant to Trastuzumab therapy (96).